Abstract 50P
Background
Activating mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS) are detected in over 1/3 of non–small-cell lung cancer (NSCLC) subtype, representing the most prevalent genomic driver event. Mostly located in codons 12 and 13, the most frequent is the p.Gly12Cys (c.34G.T) (G12C), representing about 20-25% of KRAS drive mutations in NSCLs, but remains scarce. The impact of them on prognosis is currently subject to debate, as is their impact on the response to chemotherapy and EGFR tyrosine kinase inhibitors. Our goal was to stratify our population, reporting the KRAS mutation frequency in a series of Portuguese NSCLC cases, in order to observe the incidence and impact of change of practice.
Methods
Retrospective study included NSCLC samples submitted for KRAS testing at one Portuguese center in Lisbon, between 1/1/2027 and 31/12/2021. Data cut-off was 1/9/2022. KRAS mutational status was evaluated from tumor biopsy using a new generation sequencing technique on DNA obtained to detect the most common mutations of the KRAS gene. The Oncomine™ Focus Assay panel was used in the IPATIMUP laboratory. Data was obtained from pts' clinical files and analyzed with SPSSv26.0.
Results
101 pts with NSCLC were included in our analysis, median age of 66 years (44-87), 70% male, with good performance status (70% ECOG PS 0-1). Concerning tobacco consumption, 80% were active smokers. Regarding tumor characteristics, all cases were adenocarcinomas, with 46% N1 at diagnosis and 56% of pts M1 ad initium. 10% were relapses. PDL1 status was positive in 40% of pts, and unknown in 2%. Mutation KRAS G12C was the status most frequent, identified in 36,6% of the population including c.34G>T p.Gly12Cys (36 pts) and c.35G>A p.Gly12Cys (1 pt). Followed by c.35G>T p.Gly12Val in 21,7% (22pts), c.35G>A p.Gly12Asp in 13,8% (14pts) and c.35G>C p.Gly12Ala in 6,93% (7). 1,98% (2pts) had 2 KRAS different mutation observed c.34G>T p.Gly12Cys+c.37G>A p.Gly13Ser and c.35G>T p.Gly12Val+c427G>A p.Glu143Lys where the combinations.
Conclusions
Our representative population presented a slight raise in the frequency of the G12C mutation, showing that approximately 36% of Portuguese pts with NSCLC harbor the G12C variant, thus potentially responsive to the new anti-KRAS agents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74P - Tumor agnostic comparison of immunohistochemistry and next-generation sequencing in detecting ALK fusions and assessment of ALK tyrosine kinase inhibitor efficacy
Presenter: Monica Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Target identification by TIME phenotypes
Presenter: Robert Seitz
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Prediction of response to palliative chemotherapy by circulating tumor DNA (ctDNA) kinetics in metastatic pancreatic cancer
Presenter: Patrick Kirchweger
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - High resolution in situ analysis reveals phenotypic and functional diversification within single pancreatic tumour ducts
Presenter: Ellis Michiels
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Implementing genomic profiling as standard-of-care for glioblastoma patients
Presenter: Vincent Fougner
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Cyclic fasting-mimicking diet as a strategy to improve the efficacy of standard antitumor therapies in cancer patients
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of response-predictive biomarkers for lisavanbulin: A phase II study in patients with recurrent glioblastoma
Presenter: Juanita Lopez
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Racial disparities in phase I lung cancer clinical trials
Presenter: Rohit Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
Presenter: Antoine Mavrikios
Session: Cocktail & Poster Display session
Resources:
Abstract